Gu J.,Tongji University |
Tang S.-J.,Capital Medical University |
Tan S.-Y.,Guangzhou Chest Hospital |
Wu Q.,Tianjin Haihe Hospital |
And 10 more authors.
International Journal of Clinical and Experimental Medicine | Year: 2015
Objective: To assess the clinical efficacy and safety of Silibinin in preventing drug-induced liver injury (DILI) in the general population (high-risk patients with non-drug induced liver injury). Method: A prospective, multi-center, randomized, open-label and controlled trial was conducted with 568 patients undergoing primary treatment of pulmonary tuberculosis. The study included 277 patients in experimental group and 291 patients in control group. The patients in the two group were treated with conventional 2HREZ (S)/4HR for tuberculosis (TB), and additional Silibinin capsules (oral administration of 70 mg/time, 3 times/day for 8 weeks in experimental group. Outcomes of liver function, interruption of anti-TB treatment and therapeutic results, as well as adverse reactions were observed and analyzed. Results: At 2, 4 and 8 weeks of treatment, the incidences of liver injury in experimental group were 3.97%, 1.44% and 2.17%, respectively; the incidences in control group were 4.12%, 4.12% and 2.41%, respectively. Statistical analysis showed that there was no difference in the incidence between the two groups at each treatment period (P>0.05). At 8 weeks, the numbers of patients diagnosed of DILI were 18 (7.22%) and 27 (9.28%) in experimental and control groups, respectively (P>0.05). 34.30% and 27.49% of the patients in experimental and control groups had transient abnormal liver function or symptoms, respectively; similar percentages (3.25% and 6.19%) of the patients in two groups have liver function injury and symptoms, and were suspended for anti-TB treatment (P>0.05). The incidence of anorexia and nausea symptoms was lower in experimental group than in control group, and the differences were significant at 4 and 8 weeks (P<0.05). 8 weeks after the treatment, 98.30% of the sputum smear culture were negative in experimental group, which was significantly higher (P<0.01) than that in control group (92.98%). Conclusion: Preventive hepatoprotective therapy in the general population may reduce drug discontinuation rate, improve patient’s compliance and outcomes of anti-TB treatment. © 2015, Int J Clin Exp Med. All rights reserved.
Huang L.-H.,Wuxi Infectious Disease Hospital |
Yao Y.-P.,Wuxi Infectious Disease Hospital
World Chinese Journal of Digestology | Year: 2011
Reactivation of hepatitis B virus (HBV) is a frequent complication of chemotherapy in patients with HBV infection. Reactivation is characterized by increased levels of serum HBV DNA, abnormal liver function and hepatic failure. HBV reactivation inevitably leads to disruption of chemotherapy and severe clinical results in some cases. Nucleoside analogues play an important role in preventing and reducing the risk for HBV reactivation and HBV-associated morbidity and mortality. This paper gives a systematic review of the definition, mechanism and causes of HBV reactivation and summarizes the principles and problems for antiviral treatment in patients with HBV reactivation. It is strongly recommended that all patients should be screened for HBV serum markers before chemotherapy and preventive therapy with nucleoside analogues be given in patients with HBV. The use of potent antiviral drugs with low resistance potential and close viral monitoring during therapy are important for patients with HBV infection undergoing chemotherapy.
Mu X.-H.,Third Hospital of Kunshan |
Wu P.-F.,Third Hospital of Kunshan |
Hua H.-Y.,Jiangsu Provincial Institute of Parasitic Diseases |
Huang L.-H.,Wuxi Infectious Disease Hospital |
And 6 more authors.
Chinese Journal of Schistosomiasis Control | Year: 2011
Objective: To evaluate the therapeutic effect and safety of Dahuangzhechong pills on advanced schistosomiasis. Methods: Sixty-two patients with advanced schistosomiasis were divided randomly into two groups, a treatment group and a control group, and treated with Dahuangzhechong pills and routine therapy, respectively. The course of treatment was 52 weeks in the two groups. Before and after the 52-week treatment, the indexes of liver function and hepatic fibrosis, prothrombin time (PT), Child -Pugh scores and changes of B-type ultrasonic images were detected for all the patients. Results: There were significant differences in the levels of alanine aminotransferase (ALT) and total bilirubin (TBIL), the indexes of hepatic fibrosis, portal venous inside diameters and portal venous flow between the two groups after 52 weeks treatment (P < 0.05). In addition, there were no obvious adverse effects during the treatment in the patients of the Dahuangzhechong pill group. Conclusion: Dahuangzhechong pill treatment is a safe and effective therapy for the patients with advanced schistosomiasis.
Lu Z.H.,Wuxi Infectious Disease Hospital |
Chen W.,Wuxi Infectious Disease Hospital |
Ju Z.C.,Wuxi Infectious Disease Hospital |
Pei H.,Wuxi Infectious Disease Hospital |
And 3 more authors.
Journal of International Medical Research | Year: 2011
This retrospective study examined 220 Chinese chronic hepatitis B virus carriers over 5 years. After initial liver biopsy, liver function tests and serological analysis, patients underwent further tests of liver function and hepatitis B seromarkers at 6-month intervals. Second and third liver biopsies were performed in 56 and 23 patients, respectively. Liver pathology was classified according to inflammatory activity (G0-G4) and degree of fibrosis (S0-S4). A significantly greater proportion of hepatitis B e antigen antibody-positive patients had a more severe level of inflammation and fibrosis than patients who were hepatitis B e antigen (HBeAg)-positive. Abnormal inflammation (≥ G2) occurred in 122 (55.5%) patients. Hepatitis B reactivation occurred in 35 (15.9%) patients: 33 had obvious liver inflammation at the initial biopsy (≥ G2) and only two had a low level of liver inflammation (G0-G1). The hepatitis B reactivation rate was significantly related to age but not to gender. Hepatitis B surface antigen clearance was 1.55% per year and HBeAg seroconversion was 5.36% per year. In conclusion, hepatitis B reactivation was closely correlated with age and the level of liver inflammation. © 2011 Field House Publishing LLP.